Korean J Hematol 2001; 36(4):
Published online December 31, 2001
© The Korean Society of Hematology
김유리, 황지연, 김춘추, 김동욱
가톨릭대학교 의과대학 가톨릭조혈모세포이식센터,
분자 혈액학 연구실
Background:
The BCR-ABL rearrangement, the molecular hallmark of chronic myeloid leukemia(CML) can be used as a marker to identify residual disease after therapy. So far, very limited data exists in Korea regarding the frequenct of BCR-ABL fusion gene in parients with CML. The objective of this study was to identify the type of BCR-ABL fusion variants of CML patients in Korea.
method:
We performed a two-step reverse transcription-polymerase chain reaction(RT-PCR) to detect BCR-ABL specific mRNA in 154 CML patients who were diagnosed by histologic examination and cytogenetics at our institute between January 1997 and November 2000. We used different promer set to amplify various breakpoints of BCR-ABL fusion gene.
result:
All patients chowed at least one of BCR-ABL transcripts. One hundred and four of 154 patients (67.5%) represented b3a2 transcript that was most frequent transcript in our CML patients. 44 patients (28.6%) ahd b2a2 transcript and b3a2+b2a2 splicing variants were identified in 5 cases (3.25%). In addition, c3a2 variant which is very rare transcript was identified in a patient (0.65%).
conclusions:
The RT-PCR assay could identify the presence of the BCR-ABL transcript in all patients with exquisite sensitivity. The frequency of BCR-ABL transcript was different from that of western countries but similar to that of eastern. Long-term follow up of CML patients with different variants are needed to determine the prognostic importance of each gene variant. (Korean J Hematol 2001;36:292 ~ 298)
Keywords BCR-ABL, CML, RT-PCR
Korean J Hematol 2001; 36(4): 292-298
Published online December 31, 2001
Copyright © The Korean Society of Hematology.
김유리, 황지연, 김춘추, 김동욱
가톨릭대학교 의과대학 가톨릭조혈모세포이식센터,
분자 혈액학 연구실
Yoo Li Kim, Ji Yeon Hwang, Chun Choo Kim, Dong Wook Kim
Molecular Hematology Laboratory, Catholic Hemopoietic Stem Transplantation Center, The Catholic University of Korea, College of Medicine, Seoul, Korea
Background:
The BCR-ABL rearrangement, the molecular hallmark of chronic myeloid leukemia(CML) can be used as a marker to identify residual disease after therapy. So far, very limited data exists in Korea regarding the frequenct of BCR-ABL fusion gene in parients with CML. The objective of this study was to identify the type of BCR-ABL fusion variants of CML patients in Korea.
method:
We performed a two-step reverse transcription-polymerase chain reaction(RT-PCR) to detect BCR-ABL specific mRNA in 154 CML patients who were diagnosed by histologic examination and cytogenetics at our institute between January 1997 and November 2000. We used different promer set to amplify various breakpoints of BCR-ABL fusion gene.
result:
All patients chowed at least one of BCR-ABL transcripts. One hundred and four of 154 patients (67.5%) represented b3a2 transcript that was most frequent transcript in our CML patients. 44 patients (28.6%) ahd b2a2 transcript and b3a2+b2a2 splicing variants were identified in 5 cases (3.25%). In addition, c3a2 variant which is very rare transcript was identified in a patient (0.65%).
conclusions:
The RT-PCR assay could identify the presence of the BCR-ABL transcript in all patients with exquisite sensitivity. The frequency of BCR-ABL transcript was different from that of western countries but similar to that of eastern. Long-term follow up of CML patients with different variants are needed to determine the prognostic importance of each gene variant. (Korean J Hematol 2001;36:292 ~ 298)
Keywords: BCR-ABL, CML, RT-PCR
Young Kyung Lee, Sung Sup Park, Eun Kyung Ra, Ji Yeon Kim, Young Joon Lee, Han lk Cho
Korean J Hematol 2000; 35(1): 27-33Dong-Wook Kim
Korean J Hematol 2011; 46(3): 169-174Mabel Lardo, Marcelo Castro, Beatriz Moiraghi, Francisca Rojas, Natalia Borda, Jorge A Rey, and Alberto Lazarowski
Blood Res 2015; 50(3): 154-159